NHS
Pan Mersey
Area Prescribing Committee

FLUOCINOLONE intravitreal implant (Iluvien®) for chronic diabetic macular oedema in phakic eyes

The Pan Mersey Area Prescribing Committee does not recommend the prescribing of FLUOCINOLONE intravitreal implant (Iluvien®) for treating chronic diabetic macular oedema in phakic eyes after an inadequate response to previous therapy, in accordance with NICE TA613

BLACK

FLUOCINOLONE intravitreal implant (Iluvien®) is licensed for the treatment of vision impairment associated with chronic diabetic macular oedema (DMO) considered insufficiently responsive to available therapies.

This statement refers **ONLY** to the indication for chronic diabetic macular oedema in **PHAKIC EYES.**
For the treatment of DMO in patients with pseudophakic eyes, please see NICE TA301 (November 2013).

NICE technology appraisal TA613 does **NOT** recommend FLUOCINOLONE intravitreal implant (Iluvien®) as an option for treating chronic diabetic macular oedema that is insufficiently responsive to available therapies in an eye with a natural lens (phakic eye).[1]

NICE technology appraisal TA613[1] does **NOT** recommend FLUOCINOLONE intravitreal implant (Iluvien®) for treating chronic diabetic macular oedema in phakic eyes after an inadequate response to previous therapy for the following reasons:

- The lack of clinical evidence makes it difficult to establish if fluocinolone acetonide intravitreal implant works better than usual care for these people, especially in the long term.
- Because of the lack of clinical evidence, the cost-effectiveness estimates for fluocinolone acetonide intravitreal implant are also uncertain.
- Even the lowest clinically plausible cost-effectiveness estimates are substantially higher than what NICE normally considers an acceptable use of NHS resources.

References

1. National Institute for Health and Care Excellence. Technology Appraisal 613: Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema in phakic eyes after an inadequate response to previous therapy; 20 November 2019. Accessed 21 November 2019.

Note: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.